XML 27 R15.htm IDEA: XBRL DOCUMENT v3.22.1
EARNINGS PER SHARE
 12 Months Ended
Apr. 02, 2022
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.
(In thousands, except per share amounts)202220212020
Basic EPS   
Net income$43,375 $79,469 $76,526 
Weighted average shares51,047 50,688 50,692 
Basic income per share$0.85 $1.57 $1.51 
Diluted EPS   
Net income$43,375 $79,469 $76,526 
Basic weighted average shares51,047 50,688 50,692 
Net effect of common stock equivalents306 604 1,123 
Diluted weighted average shares51,353 51,292 51,815 
Diluted income per share$0.84 $1.55 $1.48 

Basic earnings per share is calculated using the Company's weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company's common shares has been less than the initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion value of the convertible senior notes. For fiscal 2022, 2021 and 2020, weighted average shares outstanding, assuming dilution, excludes the impact of 0.9 million, 0.5 million and 0.2 million anti-dilutive shares, respectively.

Share Repurchase Plan

In May 2019, the Company's Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the two year period ending May 2021. During fiscal 2022, the Company did not make any additional repurchases under this program, which expired in May 2021.